

13

18,19,20-tetranor-5,13-prostadienoic acid; (5Z)-(9R,11R, 15R)-9-chloro-15-cyclohexyl-11,15-dihydroxy-16,17,18, 19,20-pentanor-5-prostenoic acid isopropyl ester; (5Z)-(9S, 11R,15S)-15-cyclohexyl-9,11,15-trihydroxy-16,17,18,19, 20-pentanor-5-prostenoic acid isopropyl ester; (5Z,13E)-(9S,11R,15R)-9,11,15-trihydroxy-16-(3-chlorophenoxy)- 17,18,19,20-tetranor-5,13-prostadienoic acid amide; PGF_{2α} isopropyl ester; fluprostenol isopropyl ester; and isopropyl [2R(1E,3R),3S(4Z),4R]-7-[tetrahydro-2-[4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-4-hydroxy-3-furanyl]-4-heptenoate.

16. The method of claim **15** wherein the composition comprises 0.001–0.005% (w/v) prostaglandin; 0.5%(w/v) PEG-40 hydrogenated castor oil; 0.12%(w/v) tromethamine; 0.3%(w/v) boric acid; 4.6%(w/v) mannitol; 0.01%(w/v) disodium edetate; and 0.015%(w/v) benzalkonium chloride; and the prostaglandin is selected from the group consisting of fluprostenol isopropyl ester and isopropyl [2R(1E,3R),3S(4Z),4R]-7-[tetrahydro-2-[4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-4-hydroxy-3-furanyl]-4-heptenoate.

14

17. The method of claim **16** wherein the fluprostenol isopropyl ester is 1R-[1α(Z),2β(1E,3R*),3α,5α]-7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)-phenoxy]-1-but enyl]cyclopentyl]-5-heptenoic acid, 1-methylethyl ester.

18. The method of claim **15** wherein the composition comprises 0.002%(w/v) 1R-[1α(Z),2β(1E,3R*),3α,5α]-7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)-phenoxy]-1-but enyl]cyclopentyl]-5-heptenoic acid, 1-methylethyl ester; 0.02%(w/v) brimonidine; 0.5%(w/v) PEG-40 hydrogenated castor oil; 0.785%(w/v) tromethamine; 0.6%(w/v) boric acid; 4.25%(w/v) mannitol; 0.01%(w/v) disodium edetate; and 0.015%(w/v) benzalkonium chloride.

19. The method of claim **12** wherein the composition is a topically administrable ophthalmic composition.

20. The method of claim **12** wherein the amount of hydrogenated polyethoxylated castor oil is between about 0.02 and 20 wt. %.

* * * * *